Integrating genomics with the gut-brain axis: current evidence in autism spectrum disorder, epilepsy, schizophrenia, and emerging future challenges

Ericka C. Loza López , Gabriela Cano-Herrera , Maria F. Bautista Gonzalez , Amairani Méndez Vionet , Ximena A. Van Tienhoven , Emmanuel Simental Aldaba , Enrique de Jesús Guzmán Argüelles , Renata Murguiondo Pérez , Patricia Carolina Massieu Pérez , Diego De León Vela , Layra Mena García , Itzel Valeria Alpizar Andrade , Felipe Esparza Salazar

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004146

PDF (5017KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004146 DOI: 10.37349/ent.2026.1004146
Review
research-article
Integrating genomics with the gut-brain axis: current evidence in autism spectrum disorder, epilepsy, schizophrenia, and emerging future challenges
Author information +
History +
PDF (5017KB)

Abstract

The relationship between the gut microbiota and the central nervous system has gained attention as a biological axis that may influence the development of several neurological disorders. Recent evidence integrating genomic, neurobiological, and microbiota research shows how bacterial composition, host genetic variability, and the mechanisms of the microbiota-gut-brain axis interact in conditions such as autism spectrum disorder, epilepsy, and schizophrenia. These interactions function through neural, metabolic, and immunological related pathways involving intestinal and blood-brain barrier permeability. Genome-wide association studies (GWAS) and Mendelian randomization analyses highlight shared immunogenetic pathways that may shape both microbial profiles and neurological susceptibility. Consistent patterns of dysbiosis and alterations in neuroactive metabolites have also been reported, linking microbiota changes to neuroinflammation and disrupted neuronal signaling. This review synthesizes the current evidence supporting the integration of the microbiota-gut-brain axis and its underlying communication pathways. It also outlines the present therapeutic strategies for neurological disorders such as autism spectrum disorder, epilepsy, and schizophrenia, highlighting their potential to modulate neurological function. Additionally, it discusses the existing limitations in the field and offers insights into future research directions within this rapidly evolving area.

Keywords

gut-brain axis / microbiota / autism spectrum disorder / epilepsy / schizophrenia

Cite this article

Download citation ▾
Ericka C. Loza López, Gabriela Cano-Herrera, Maria F. Bautista Gonzalez, Amairani Méndez Vionet, Ximena A. Van Tienhoven, Emmanuel Simental Aldaba, Enrique de Jesús Guzmán Argüelles, Renata Murguiondo Pérez, Patricia Carolina Massieu Pérez, Diego De León Vela, Layra Mena García, Itzel Valeria Alpizar Andrade, Felipe Esparza Salazar. Integrating genomics with the gut-brain axis: current evidence in autism spectrum disorder, epilepsy, schizophrenia, and emerging future challenges. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004146 DOI:10.37349/ent.2026.1004146

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Xu L, Li M, Wang Z, Li Q. Global trends and burden of idiopathic epilepsy: regional and gender differences from 1990 to 2021 and future outlook. J Health Popul Nutr. 2025; 44: 45.

[2]

Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr Bull. 2018; 44: 1195-203.

[3]

Myers SM, Voigt RG, Colligan RC, Weaver AL, Storlie CB, Stoeckel RE, et al. Autism Spectrum Disorder: Incidence and Time Trends Over Two Decades in a Population-Based Birth Cohort. J Autism Dev Disord. 2019; 49: 1455-74.

[4]

Feigin VL, Vos T, Nair BS, Hay SI, Abate YH, Abd Al Magied AHA, et al. Global, regional, and national burden of epilepsy, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2025; 10: e203-27.

[5]

Arias D, Saxena S, Verguet S. Quantifying the global burden of mental disorders and their economic value. EClinicalMedicine. 2022; 54: 101675.

[6]

Bashir Y, Khan AU. The interplay between the gut-brain axis and the microbiome: A perspective on psychiatric and neurodegenerative disorders. Front Neurosci. 2022; 16: 1030694.

[7]

Rothwell J, Antal A, Burke D, Carlsen A, Georgiev D, Jahanshahi M, et al. Central nervous system physiology. Clin Neurophysiol. 2021; 132: 3043-83.

[8]

Agrawal P, Mendhey P, Kumar R, Patel S, Kaushik PK, Dadsena A, et al. Introduction to microbiomes in health and diseases. Int Rev Cell Mol Biol. 2025; 394: 1-42.

[9]

Chaudhary PP, Kaur M, Myles IA. Does “all disease begin in the gut”? The gut-organ cross talk in the microbiome. Appl Microbiol Biotechnol. 2024; 108: 339.

[10]

Ahlawat S, Asha, Sharma KK. Gut-organ axis: a microbial outreach and networking. Lett Appl Microbiol. 2021; 72: 636-68.

[11]

Feng Q, Chen W, Wang Y. Gut Microbiota: An Integral Moderator in Health and Disease. Front Microbiol. 2018; 9: 151.

[12]

Mottahedin A, Ardalan M, Chumak T, Riebe I, Ek J, Mallard C. Effect of Neuroinflammation on Synaptic Organization and Function in the Developing Brain: Implications for Neurodevelopmental and Neurodegenerative Disorders. Front Cell Neurosci. 2017; 11: 190.

[13]

Damiani F, Cornuti S, Tognini P. The gut-brain connection: Exploring the influence of the gut microbiota on neuroplasticity and neurodevelopmental disorders. Neuropharmacology. 2023; 231: 109491.

[14]

Lu S, Zhao Q, Guan Y, Sun Z, Li W, Guo S, et al. The communication mechanism of the gut-brain axis and its effect on central nervous system diseases: A systematic review. Biomed Pharmacother. 2024; 178: 117207.

[15]

Góralczyk-Bińkowska A, Szmajda-Krygier D, Kozłowska E. The Microbiota-Gut-Brain Axis in Psychiatric Disorders. Int J Mol Sci. 2022; 23: 11245.

[16]

Sorboni SG, Moghaddam HS, Jafarzadeh-Esfehani R, Soleimanpour S. A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders. Clin Microbiol Rev. 2022; 35:e0033820.

[17]

Kelly JR, Minuto C, Cryan JF, Clarke G, Dinan TG. Cross Talk: The Microbiota and Neurodevelopmental Disorders. Front Neurosci. 2017; 11: 490.

[18]

Mathew NE, McCaffrey D, Walker AK, Mallitt K, Masi A, Morris MJ, et al. The search for gastrointestinal inflammation in autism: a systematic review and meta-analysis of non-invasive gastrointestinal markers. Mol Autism. 2024; 15: 4.

[19]

Nikolova VL, Smith MRB, Hall LJ, Cleare AJ, Stone JM, Young AH. Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis. JAMA Psychiatry. 2021; 78: 1343-54.

[20]

Xie Y, Zhao Y, Zhou Y, Jiang Y, Zhang Y, Du J, et al. Shared Genetic Architecture Among Gastrointestinal Diseases, Schizophrenia, and Brain Subcortical Volumes. Schizophr Bull. 2024; 50: 1243-54.

[21]

Nakhal MM, Yassin LK, Alyaqoubi R, Saeed S, Alderei A, Alhammadi A, et al. The Microbiota-Gut-Brain Axis and Neurological Disorders: A Comprehensive Review. Life (Basel). 2024; 14: 1234.

[22]

Mhanna A, Alshehabi Z. The microbiota-gut-brain axis and three common neurological disorders: a mini-review. Ann Med Surg (Lond). 2023; 85: 1780-3.

[23]

Deng H, He L, Wang C, Zhang T, Guo H, Zhang H, et al. Altered gut microbiota and its metabolites correlate with plasma cytokines in schizophrenia inpatients with aggression. BMC Psychiatry. 2022; 22: 629.

[24]

Li Z, Tao X, Wang D, Pu J, Liu Y, Gui S, et al. Alterations of the gut microbiota in patients with schizophrenia. Front Psychiatry. 2024; 15: 1366311.

[25]

Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. Cell. 2016; 167: 915-32.

[26]

Riazi K, Galic MA, Kuzmiski JB, Ho W, Sharkey KA, Pittman QJ. Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci U S A. 2008; 105: 17151-6.

[27]

Riazi K, Galic MA, Pittman QJ. Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res. 2010; 89: 34-42.

[28]

Goodrich JK, Waters JL, Poole AC, Sutter JL, Koren O, Blekhman R, et al. Human genetics shape the gut microbiome. Cell. 2014; 159: 789-99.

[29]

Asensio EM, Ortega-Azorín C, Barragán R, Alvarez-Sala A, Sorlí JV, Pascual EC, et al. Association between Microbiome-Related Human Genetic Variants and Fasting Plasma Glucose in a High- Cardiovascular-Risk Mediterranean Population. Medicina (Kaunas). 2022; 58: 1238.

[30]

Doenyas C, Clarke G, Cserjési R. Gut-brain axis and neuropsychiatric health: recent advances. Sci Rep. 2025; 15: 3415.

[31]

Mukhopadhya I, Louis P. Gut microbiota-derived short-chain fatty acids and their role in human health and disease. Nat Rev Microbiol. 2025; 23: 635-51.

[32]

Schiweck C, Thanarajah SE, Aichholzer M, Matura S, Reif A, Vrieze E, et al. Regulation of CD4+ and CD8+ T Cell Biology by Short-Chain Fatty Acids and Its Relevance for Autoimmune Pathology. Int J Mol Sci. 2022; 23: 8272.

[33]

Chakrabarti A, Geurts L, Hoyles L, Iozzo P, Kraneveld AD, La Fata G, et al. The microbiota-gut-brain axis: pathways to better brain health. Perspectives on what we know, what we need to investigate and how to put knowledge into practice. Cell Mol Life Sci. 2022; 79: 80.

[34]

Colombo AV, Sadler RK, Llovera G, Singh V, Roth S, Heindl S, et al. Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition. Elife. 2021; 10: e59826.

[35]

Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015; 18: 965-77.

[36]

Chen M, Ruan G, Chen L, Ying S, Li G, Xu F, et al. Neurotransmitter and Intestinal Interactions: Focus on the Microbiota-Gut-Brain Axis in Irritable Bowel Syndrome. Front Endocrinol (Lausanne). 2022; 13: 817100.

[37]

Mann ER, Lam YK, Uhlig HH. Short-chain fatty acids: linking diet, the microbiome and immunity. Nat Rev Immunol. 2024; 24: 577-95.

[38]

O’Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015; 277: 32-48.

[39]

Parker A, Fonseca S, Carding SR. Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health. Gut Microbes. 2020; 11: 135-57.

[40]

Wang Q, Yang Q, Liu X. The microbiota-gut-brain axis and neurodevelopmental disorders. Protein Cell. 2023; 14: 762-75.

[41]

Taniguchi K, Ikeda Y, Nagase N, Tsuji A, Kitagishi Y, Matsuda S. Implications of Gut-Brain axis in the pathogenesis of Psychiatric disorders. AIMS Bioeng. 2021; 8: 243-56.

[42]

Gao K, Mu CL, Farzi A, Zhu WY. Tryptophan Metabolism: A Link Between the Gut Microbiota and Brain. Adv Nutr. 2020; 11: 709-23.

[43]

Choi J, Lee S, Won J, Jin Y, Hong Y, Hur TY, et al. Pathophysiological and neurobehavioral characteristics of a propionic acid-mediated autism-like rat model. PLoS One. 2018; 13: e0192925.

[44]

Silva YP, Bernardi A, Frozza RL. The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut- Brain Communication. Front Endocrinol (Lausanne). 2020; 11: 25.

[45]

Gong W, Guo P, Li Y, Liu L, Yan R, Liu S, et al. Role of the Gut-Brain Axis in the Shared Genetic Etiology Between Gastrointestinal Tract Diseases and Psychiatric Disorders: A Genome-Wide Pleiotropic Analysis. JAMA Psychiatry. 2023; 80: 360-70.

[46]

Xiao L, Liu S, Wu Y, Huang Y, Tao S, Liu Y, et al. The interactions between host genome and gut microbiome increase the risk of psychiatric disorders: Mendelian randomization and biological annotation. Brain Behav Immun. 2023; 113: 389-400.

[47]

Martins-Silva T, Salatino-Oliveira A, Genro JP, Meyer FDT, Li Y, Rohde LA, et al. Host genetics influences the relationship between the gut microbiome and psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2021; 106: 110153.

[48]

Xu F, Fu Y, Sun TY, Jiang Z, Miao Z, Shuai M, et al. The interplay between host genetics and the gut microbiome reveals common and distinct microbiome features for complex human diseases. Microbiome. 2020; 8: 145.

[49]

Yue Q, Cai M, Xiao B, Zhan Q, Zeng C. The Microbiota-Gut-Brain Axis and Epilepsy. Cell Mol Neurobiol. 2022; 42: 439-53.

[50]

Mengoli M, Conti G, Fabbrini M, Candela M, Brigidi P, Turroni S, et al. Microbiota-gut-brain axis and ketogenic diet: how close are we to tackling epilepsy? Microbiome Res Rep. 2023; 2: 32.

[51]

Peng A, Qiu X, Lai W, Li W, Zhang L, Zhu X, et al. Altered composition of the gut microbiome in patients with drug-resistant epilepsy. Epilepsy Res. 2018; 147: 102-7.

[52]

Gronier B, Savignac HM, Di Miceli M, Idriss SM, Tzortzis G, Anthony D, et al. Increased cortical neuronal responses to NMDA and improved attentional set-shifting performance in rats following prebiotic (B-GOS®) ingestion. Eur Neuropsychopharmacol. 2018; 28: 211-24.

[53]

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11: 506-14.

[54]

Szeligowski T, Yun AL, Lennox BR, Burnet PWJ. The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications. Front Psychiatry. 2020; 11: 156.

[55]

Kim S, Park S, Choi TG, Kim SS. Role of Short Chain Fatty Acids in Epilepsy and Potential Benefits of Probiotics and Prebiotics: Targeting “Health” of Epileptic Patients. Nutrients. 2022; 14: 2982.

[56]

Mazzone L, Dooling SW, Volpe E, Uljarević M, Waters JL, Sabatini A, et al. Precision microbial intervention improves social behavior but not autism severity: A pilot double-blind randomized placebo-controlled trial. Cell Host Microbe. 2024; 32: 106-16.e6.

[57]

Critchfield JW, van Hemert S, Ash M, Mulder L, Ashwood P. The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract. 2016; 2016: 161358.

[58]

Cocean AM, Vodnar DC. Exploring the gut-brain Axis: Potential therapeutic impact of Psychobiotics on mental health. Prog Neuropsychopharmacol Biol Psychiatry. 2024; 134: 111073.

[59]

Garzone S, Charitos IA, Mandorino M, Maggiore ME, Capozzi L, Cakani B, et al. Can We Modulate Our Second Brain and Its Metabolites to Change Our Mood? A Systematic Review on Efficacy, Mechanisms, and Future Directions of “Psychobiotics”. Int J Mol Sci. 2025; 26: 1972.

[60]

Bauer Estrada K, Conde-Martínez N, Acosta-González A, Díaz-Barrera LE, Rodríguez-Castaño GP, Quintanilla-Carvajal MX. Synbiotics of encapsulated Limosilactobacillus fermentum K73 promotes in vitro favorable gut microbiota shifts and enhances short-chain fatty acid production in fecal samples of children with autism spectrum disorder. Food Res Int. 2025; 209: 116227.

[61]

Makkawi S, Camara-Lemarroy C, Metz L. Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS. Neurol Neuroimmunol Neuroinflamm. 2018; 5: e459.

[62]

Elangovan S, Borody TJ, Holsinger RMD. Fecal Microbiota Transplantation Reduces Pathology and Improves Cognition in a Mouse Model of Alzheimer’s Disease. Cells. 2022; 12: 119.

[63]

Zhao Z, Ning J, Bao XQ, Shang M, Ma J, Li G, et al. Fecal microbiota transplantation protects rotenone- induced Parkinson’s disease mice via suppressing inflammation mediated by the lipopolysaccharide- TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome. 2021; 9: 226.

[64]

Steenbergen L, Maraver MJ, Actis-Grosso R, Ricciardelli P, Colzato LS. Recognizing emotions in bodies: Vagus nerve stimulation enhances recognition of anger while impairing sadness. Cogn Affect Behav Neurosci. 2021; 21: 1246-61.

[65]

Gulliver EL, Young RB, Chonwerawong M, D’Adamo GL, Thomason T, Widdop JT, et al. Review article: the future of microbiome-based therapeutics. Aliment Pharmacol Ther. 2022; 56: 192-208.

[66]

Lynch LE, Lahowetz R, Maresso C, Terwilliger A, Pizzini J, Melendez Hebib V, et al. Present and future of microbiome-targeting therapeutics. J Clin Invest. 2025; 135: e184323.

[67]

Walter J, Armet AM, Finlay BB, Shanahan F. Establishing or Exaggerating Causality for the Gut Microbiome: Lessons from Human Microbiota-Associated Rodents. Cell. 2020; 180: 221-32.

[68]

Ryu G, Kim H, Koh A. Approaching precision medicine by tailoring the microbiota. Mamm Genome. 2021; 32: 206-22.

[69]

Lange L, Berg G, Cernava T, Champomier-Vergès MC, Charles T, Cocolin L, et al. Microbiome ethics, guiding principles for microbiome research, use and knowledge management. Environ Microbiome. 2022; 17: 50.

[70]

Xiao Y, Louwies T, Mars RAT, Kashyap PC. The Human Microbiome-A Physiologic Perspective. Compr Physiol. 2024; 14: 5491-519.

[71]

Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, et al. Short-Chain Fatty-Acid- Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients. 2023; 15: 2211.

[72]

Cong J, Zhou P, Zhang R. Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease. Nutrients. 2022; 14: 1977.

[73]

Kaur H, Bose C, Mande SS. Tryptophan Metabolism by Gut Microbiome and Gut-Brain-Axis: An in silico Analysis. Front Neurosci. 2019; 13: 1365.

[74]

Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019; 16: 461-78.

[75]

Gan Y, Chen Y, Zhong H, Liu Z, Geng J, Wang H, et al. Gut microbes in central nervous system development and related disorders. Front Immunol. 2024; 14: 1288256.

[76]

Dash S, Syed YA, Khan MR. Understanding the Role of the Gut Microbiome in Brain Development and Its Association With Neurodevelopmental Psychiatric Disorders. Front Cell Dev Biol. 2022; 10: 880544.

[77]

Frerichs NM, de Meij TGJ, Niemarkt HJ. Microbiome and its impact on fetal and neonatal brain development: current opinion in pediatrics. Curr Opin Clin Nutr Metab Care. 2024; 27: 297-303.

[78]

Gulas E, Wysiadecki G, Strzelecki D, Gawlik-Kotelnicka O, Polguj M. Can microbiology affect psychiatry? A link between gut microbiota and psychiatric disorders. Psychiatr Pol. 2018; 52: 1023-39.

[79]

Pronovost GN, Hsiao EY. Perinatal Interactions between the Microbiome, Immunity, and Neurodevelopment. Immunity. 2019; 50: 18-36.

[80]

Volpedo G, Riva A, Nobili L, Zara F, Ravizza T, Striano P. Gut-immune-brain interactions during neurodevelopment: from a brain-centric to a multisystem perspective. BMC Med. 2025; 23: 263.

[81]

Walker RW, Clemente JC, Peter I, Loos RJF. The prenatal gut microbiome: does it exist? Int J Obes. 2017; 41: 775-83.

[82]

Linehan K, Dempsey EM, Ryan CA, Ross RP, Stanton C. First encounters of the microbial kind: perinatal factors direct infant gut microbiome establishment. Microbiome Res Rep. 2022; 1: 10.

[83]

Muhammad F, Fan B, Wang R, Ren J, Jia S, Wang L, et al. The Molecular Gut-Brain Axis in Early Brain Development. Int J Mol Sci. 2022; 23: 15389.

[84]

Biagi E, Quercia S, Aceti A, Beghetti I, Rampelli S, Turroni S, et al. The Bacterial Ecosystem of Mother’s Milk and Infant’s Mouth and Gut. Front Microbiol. 2017; 8: 1214.

[85]

Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024; 9: 37.

[86]

Liu L, Huh JR, Shah K. Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. EBioMedicine. 2022; 77: 103908.

[87]

Longo S, Rizza S, Federici M. Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes. Acta Diabetol. 2023; 60: 1007-17.

[88]

Faraji N, Payami B, Ebadpour N, Gorji A. Vagus nerve stimulation and gut microbiota interactions: A novel therapeutic avenue for neuropsychiatric disorders. Neurosci Biobehav Rev. 2025; 169: 105990.

[89]

Bonaz B, Bazin T, Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front Neurosci. 2018; 12: 49.

[90]

Vancamelbeke M, Vermeire S. The intestinal barrier: a fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017; 11: 821-34.

[91]

Zhuang M, Zhang X, Cai J. Microbiota-gut-brain axis: interplay between microbiota, barrier function and lymphatic system. Gut Microbes. 2024; 16: 2387800.

[92]

Jenkins TA, Nguyen JC, Polglaze KE, Bertrand PP. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients. 2016; 8: 56.

[93]

Tesfaye M, Jaholkowski P, Hindley GFL, Shadrin AA, Rahman Z, Bahrami S, et al. Shared genetic architecture between irritable bowel syndrome and psychiatric disorders reveals molecular pathways of the gut-brain axis. Genome Med. 2023; 15: 60.

[94]

Dinan TG, Cryan JF. Brain-Gut-Microbiota Axis and Mental Health. Psychosom Med. 2017; 79: 920-6.

[95]

Staudacher HM, Black CJ, Teasdale SB, Mikocka-Walus A, Keefer L. Irritable bowel syndrome and mental health comorbidity-approach to multidisciplinary management. Nat Rev Gastroenterol Hepatol. 2023; 20: 582-96.

[96]

Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019; 50: 132-43.

[97]

Wang F, Liu YL, Jiang CH, Wu HY, Jin J, Sun YW, et al. Association between psychiatric disorders and irritable bowel syndrome: A bidirectional Mendelian randomization study. J Affect Disord. 2025; 368: 865-71.

[98]

Ruohan Z, Ruting W, Hongxi W, Zhenjin H, Jiale L, Rongxin Z, et al. Gut microbiota as a novel target for treating anxiety and depression: from mechanisms to multimodal interventions. Front Microbiol. 2025; 16: 1664800.

[99]

Keane L, Clarke G, Cryan JF. A role for microglia in mediating the microbiota-gut-brain axis. Nat Rev Immunol. 2025; 25: 847-61.

[100]

Kong L, Wang X, Chen G, Zhu Y, Wang L, Yan M, et al. Gut microbiome characteristics in individuals across different stages of schizophrenia spectrum disorders: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2025; 173: 106167.

[101]

Mohammed V, Muthuramamoorthy M, Arasu MV, Arockiaraj J. Gut microbiome and mitochondrial crosstalk in Schizophrenia, a mental disability: Emerging mechanisms and therapeutic targets. Neurosci Biobehav Rev. 2025; 178: 106371.

[102]

Socała K, Doboszewska U, Szopa A, Serefko A, Włodarczyk M, Zielińska A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol Res. 2021; 172: 105840.

[103]

Tao K, Yuan Y, Xie Q, Dong Z. Relationship between human oral microbiome dysbiosis and neuropsychiatric diseases: An updated overview. Behav Brain Res. 2024; 471: 115111.

[104]

Lebwohl B, Haggård L, Emilsson L, Söderling J, Roelstraete B, Butwicka A, et al. Psychiatric Disorders in Patients With a Diagnosis of Celiac Disease During Childhood From 1973 to 2016. Clin Gastroenterol Hepatol. 2021; 19: 2093-101.e13.

[105]

Breunig S, Lee YH, Karlson EW, Krishnan A, Lawrence JM, Schaffer LS, et al. Examining the genetic links between clusters of immune-mediated diseases and psychiatric disorders. Transl Psychiatry. 2025; 15: 252.

[106]

International League Against Epilepsy Consortium on Complex Epilepsies. GWAS meta-analysis of over 29,000 people with epilepsy identifies 26 risk loci and subtype-specific genetic architecture. Nat Genet. 2023; 55: 1471-82.

[107]

Huang QQ, Wigdor EM, Malawsky DS, Campbell P, Samocha KE, Chundru VK, et al. Examining the role of common variants in rare neurodevelopmental conditions. Nature. 2024; 636: 404-11.

[108]

Li C, Yang T, Ou R, Shang H. Overlapping Genetic Architecture Between Schizophrenia and Neurodegenerative Disorders. Front Cell Dev Biol. 2021; 9: 797072.

[109]

Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum disorder. Nat Rev Dis Primers. 2020; 6: 5.

[110]

Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019; 51: 431-44.

[111]

Robinson BG, Oster BA, Robertson K, Kaltschmidt JA. Loss of ASD-related molecule Cntnap2 affects colonic motility in mice. Front Neurosci. 2023; 17: 1287057.

[112]

Hosie S, Abo-Shaban T, Lee CYQ, Matta SM, Shindler A, Gore R, et al. The Emerging Role of the Gut- Brain-Microbiota Axis in Neurodevelopmental Disorders. Adv Exp Med Biol. 2022; 1383: 141-56.

[113]

Wang H, Liu S, Xie L, Wang J. Gut microbiota signature in children with autism spectrum disorder who suffered from chronic gastrointestinal symptoms. BMC Pediatr. 2023; 23: 476.

[114]

Zarimeidani F, Rahmati R, Mostafavi M, Darvishi M, Khodadadi S, Mohammadi M, et al. Gut Microbiota and Autism Spectrum Disorder: A Neuroinflammatory Mediated Mechanism of Pathogenesis? Inflammation. 2025; 48: 501-19.

[115]

Hetta HF, Alanazi FE, Alqifari SF, Ali MAS, Albalwi MA, Albalawi AA, et al. The Gut-Brain Axis in Autism: Inflammatory Mechanisms, Molecular Insights, and Emerging Microbiome-Based Therapies. Mol Neurobiol. 2025; 63: 211.

[116]

Yang H, Gong W, Hou Y, Wang Y, He P, Yu Q. Genetically predicted immune cell-mediated causal associations between 473 gut microbiome species and neurodevelopmental disorders. IBRO Neurosci Rep. 2025; 19: 894-902.

[117]

Li Z, Liu S, Liu F, Dai N, Liang R, Lv S, et al. Gut microbiota and autism spectrum disorders: a bidirectional Mendelian randomization study. Front Cell Infect Microbiol. 2023; 13: 1267721.

[118]

Beniczky S, Trinka E, Wirrell E, Abdulla F, Al Baradie R, Alonso Vanegas M, et al. Updated classification of epileptic seizures: Position paper of the International League Against Epilepsy. Epilepsia. 2025; 66: 1804-23.

[119]

Ding M, Lang Y, Shu H, Shao J, Cui L. Microbiota-Gut-Brain Axis and Epilepsy: A Review on Mechanisms and Potential Therapeutics. Front Immunol. 2021; 12: 742449.

[120]

Jacobs S, Wootton O, Ives-Deliperi V, Tucker LM, Stein DJ, Dalvie S. Systematic review of genome- wide association studies (GWAS) of epilepsy identifies common risk variants and associated genes. World J Biol Psychiatry. 2025; 26: 37-48.

[121]

Zhang MW, Liang XY, Wang J, Gao LD, Liao HJ, He YH, et al. Epilepsy-associated genes: an update. Seizure. 2024; 116: 4-13.

[122]

Kim J, Lee HJ, Park HJ, Lee JH, Kim WJ. Genome-Wide Association Study Identifying a Novel Gene Related to a History of Febrile Convulsions in Patients With Focal Epilepsy. J Clin Neurol. 2025; 21: 123-30.

[123]

Thakran S, Guin D, Singh P, Uppili B, Ramachandran S, Kushwaha SS, et al. Genome-Wide Association Study Reveals Genetic Architecture of Common Epilepsies. Clin Genet. 2025; 108: 22-32.

[124]

Abudusalamu R, Maimaiti A, Han W, Wang X, Jiao T, Han D, et al. Genetic relationship between epilepsy and mental disorders: A comprehensive GWAS analysis. Epilepsy Behav. 2025; 171: 110500.

[125]

Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019; 381: 1753-61.

[126]

Owen MJ, Legge SE, Rees E, Walters JTR, O’Donovan MC. Genomic findings in schizophrenia and their implications. Mol Psychiatry. 2023; 28: 3638-47.

[127]

Wang J, Luo GY, Tian T, Zhao YQ, Meng SY, Wu JH, et al. Shared genetic basis and causality between schizophrenia and inflammatory bowel disease: evidence from a comprehensive genetic analysis. Psychol Med. 2024; 54: 2658-68.

[128]

Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022; 604: 502-8.

[129]

Malekpour M, Salarikia SR, Kashkooli M, Asadi-Pooya AA. The genetic link between systemic autoimmune disorders and temporal lobe epilepsy: A bioinformatics study. Epilepsia Open. 2023; 8: 509-16.

[130]

Uellendahl-Werth F, Maj C, Borisov O, Juzenas S, Wacker EM, Jørgensen IF, et al. Cross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease. Commun Biol. 2022; 5: 80.

[131]

Qian L, He X, Gao F, Fan Y, Zhao B, Ma Q, et al. Estimation of the bidirectional relationship between schizophrenia and inflammatory bowel disease using the mendelian randomization approach. Schizophrenia (Heidelb). 2022; 8: 31.

[132]

Zhou J, Fu Z, Gao Y, An C, Zhang Z, Zhong X, et al. Gut Microbiotas, Plasma Metabolites, and Autism Spectrum Disorder: A Bidirectional Mendelian Randomization Analysis. Pathogens. 2025; 14: 1137.

[133]

Malekpour M, Parhizkar M, Golabi F, Thompson R, Zakwani MA, Soleymanjahi S, et al. Exploring the shared genetic basis between autism spectrum disorder and gastrointestinal disorders: a bioinformatic study. Sci Rep. 2025; 15: 30086.

[134]

Chen C, Yang Z, Guo J, Liu Y, Yang X, Deng W, et al. Causal genetic link between gut microbiome, metabolites, and autism spectrum disorder in a European cohort. Medicine (Baltimore). 2025; 104:e46526.

[135]

Ding HT, Taur Y, Walkup JT. Gut Microbiota and Autism: Key Concepts and Findings. J Autism Dev Disord. 2017; 47: 480-9.

[136]

Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Elevated fecal short chain fatty acid and ammonia concentrations in children with autism spectrum disorder. Dig Dis Sci. 2012; 57: 2096-102.

[137]

Kang DW, Adams JB, Gregory AC, Borody T, Chittick L, Fasano A, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017; 5: 10.

[138]

Lewandowska-Pietruszka Z, Figlerowicz M, Mazur-Melewska K. Microbiota in Autism Spectrum Disorder: A Systematic Review. Int J Mol Sci. 2023; 24: 16660.

[139]

Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism--comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 2011; 11: 22.

[140]

De Angelis M, Piccolo M, Vannini L, Siragusa S, Giacomo AD, Serrazzanetti DI, et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PLoS One. 2013; 8: e76993.

[141]

Liu S, Li E, Sun Z, Fu D, Duan G, Jiang M, et al. Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. Sci Rep. 2019; 9: 287.

[142]

He J, Gong X, Hu B, Lin L, Lin X, Gong W, et al. Altered Gut Microbiota and Short-chain Fatty Acids in Chinese Children with Constipated Autism Spectrum Disorder. Sci Rep. 2023; 13: 19103.

[143]

Kang DW, Ilhan ZE, Isern NG, Hoyt DW, Howsmon DP, Shaffer M, et al. Differences in fecal microbial metabolites and microbiota of children with autism spectrum disorders. Anaerobe. 2018; 49: 121-31.

[144]

MacFabe DF. Enteric short-chain fatty acids: microbial messengers of metabolism, mitochondria, and mind: implications in autism spectrum disorders. Microb Ecol Health Dis. 2015; 26: 28177.

[145]

Yang W, Cui H, Wang C, Wang X, Yan C, Cheng W. A review of the pathogenesis of epilepsy based on the microbiota-gut-brain-axis theory. Front Mol Neurosci. 2024; 17: 1454780.

[146]

De Caro C, Leo A, Nesci V, Ghelardini C, di Cesare Mannelli L, Striano P, et al. Intestinal inflammation increases convulsant activity and reduces antiepileptic drug efficacy in a mouse model of epilepsy. Sci Rep. 2019; 9: 13983.

[147]

Li Q, Gu Y, Liang J, Yang Z, Qin J. A long journey to treat epilepsy with the gut microbiota. Front Cell Neurosci. 2024; 18: 1386205.

[148]

Xie G, Zhou Q, Qiu CZ, Dai WK, Wang HP, Li YH, et al. Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy. World J Gastroenterol. 2017; 23: 6164-71.

[149]

Cui G, Liu S, Liu Z, Chen Y, Wu T, Lou J, et al. Gut Microbiome Distinguishes Patients With Epilepsy From Healthy Individuals. Front Microbiol. 2022; 12: 696632.

[150]

Gong X, Liu X, Chen C, Lin J, Li A, Guo K, et al. Alteration of Gut Microbiota in Patients With Epilepsy and the Potential Index as a Biomarker. Front Microbiol. 2020; 11: 517797.

[151]

Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020; 6: CD001903.

[152]

Boison D. New insights into the mechanisms of the ketogenic diet. Curr Opin Neurol. 2017; 30: 187-92.

[153]

El-Shafie AM, Bahbah WA, Abd El Naby SA, Omar ZA, Basma EM, Hegazy AAA, et al. Impact of two ketogenic diet types in refractory childhood epilepsy. Pediatr Res. 2023; 94: 1978-89.

[154]

Ju S, Shin Y, Han S, Kwon J, Choi TG, Kang I, et al. The Gut-Brain Axis in Schizophrenia: The Implications of the Gut Microbiome and SCFA Production. Nutrients. 2023; 15: 4391.

[155]

Murray N, AI Khalaf S, Bastiaanssen TFS, Kaulmann D, Lonergan E, Cryan JF, et al. Compositional and Functional Alterations in Intestinal Microbiota in Patients with Psychosis or Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2023; 49: 1239-55.

[156]

Zhu F, Ju Y, Wang W, Wang Q, Guo R, Ma Q, et al. Metagenome-wide association of gut microbiome features for schizophrenia. Nat Commun. 2020; 11: 1612.

[157]

Li S, Zhuo M, Huang X, Huang Y, Zhou J, Xiong D, et al. Altered gut microbiota associated with symptom severity in schizophrenia. PeerJ. 2020; 8: e9574.

[158]

Cryan JF, O’Riordan KJ, Cowan CSM, Sandhu KV, Bastiaanssen TFS, Boehme M, et al. The Microbiota- Gut-Brain Axis. Physiol Rev. 2019; 99: 1877-2013.

[159]

Xu M, Xu X, Li J, Li F. Association Between Gut Microbiota and Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Front Psychiatry. 2019; 10: 473.

[160]

Nguyen TT, Kosciolek T, Maldonado Y, Daly RE, Martin AS, McDonald D, et al. Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects. Schizophr Res. 2019; 204: 23-9.

[161]

Jaggar M, Rea K, Spichak S, Dinan TG, Cryan JF. You’ve got male: Sex and the microbiota-gut-brain axis across the lifespan. Front Neuroendocrinol. 2020; 56: 100815.

[162]

Iglesias-Vázquez L, Van Ginkel Riba G, Arija V, Canals J. Composition of Gut Microbiota in Children with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. Nutrients. 2020; 12: 792.

[163]

Zhao H, Zhu G, Zhu T, Ding B, Xu A, Gao S, et al. Gut microbiome and metabolism alterations in schizophrenia with metabolic syndrome severity. BMC Psychiatry. 2024; 24: 529.

[164]

Ling Z, Cheng Y, Lan Z, Liu X, Zhu Z, Ding W, et al. Gut mycobiota dysbiosis and systemic immune dysfunction in Chinese schizophrenia patients with metabolic syndrome. Front Immunol. 2025; 16: 1652633.

[165]

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, et al. Extensive impact of non- antibiotic drugs on human gut bacteria. Nature. 2018; 555: 623-8.

[166]

Sarkar A, Lehto SM, Harty S, Dinan TG, Cryan JF, Burnet PWJ. Psychobiotics and the Manipulation of Bacteria-Gut-Brain Signals. Trends Neurosci. 2016; 39: 763-81.

[167]

Oroojzadeh P, Bostanabad SY, Lotfi H. Psychobiotics: the Influence of Gut Microbiota on the Gut- Brain Axis in Neurological Disorders. J Mol Neurosci. 2022; 72: 1952-64.

[168]

Skowron K, Budzyńska A, Wiktorczyk-Kapischke N, Chomacka K, Grudlewska-Buda K, Wilk M, et al. The Role of Psychobiotics in Supporting the Treatment of Disturbances in the Functioning of the Nervous System-A Systematic Review. Int J Mol Sci. 2022; 23: 7820.

[169]

Ashique S, Paul D, Debnath B, Chellappan DK, Das J, Bhui U, et al. Probiotics, psychobiotics, and postbiotics: a therapeutic modality for the management of schizophrenia. Nutr Neurosci. 2026; 29: 298-324.

[170]

Takyi E, Nirmalkar K, Adams J, Krajmalnik-Brown R. Interventions targeting the gut microbiota and their possible effect on gastrointestinal and neurobehavioral symptoms in autism spectrum disorder. Gut Microbes. 2025; 17: 2499580.

[171]

Ribera C, Sánchez-Ortí JV, Clarke G, Marx W, Mörkl S, Balanzá-Martínez V. Probiotic, prebiotic, synbiotic and fermented food supplementation in psychiatric disorders: A systematic review of clinical trials. Neurosci Biobehav Rev. 2024; 158: 105561.

[172]

Choi HH, Cho YS. Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clin Endosc. 2016; 49: 257-65.

[173]

Wang ZK, Yang YS, Chen Y, Yuan J, Sun G, Peng LH. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease. World J Gastroenterol. 2014; 20: 14805-20.

[174]

Porcari S, Benech N, Valles-Colomer M, Segata N, Gasbarrini A, Cammarota G, et al. Key determinants of success in fecal microbiota transplantation: From microbiome to clinic. Cell Host Microbe. 2023; 31: 712-33.

[175]

Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013; 155: 1451-63.

[176]

Citraro R, Lembo F, De Caro C, Tallarico M, Coretti L, Iannone LF, et al. First evidence of altered microbiota and intestinal damage and their link to absence epilepsy in a genetic animal model, the WAG/Rij rat. Epilepsia. 2021; 62: 529-41.

[177]

He Z, Cui BT, Zhang T, Li P, Long CY, Ji GZ, et al. Fecal microbiota transplantation cured epilepsy in a case with Crohn’s disease: The first report. World J Gastroenterol. 2017; 23: 3565-8.

[178]

Fadgyas-Stanculete M, Buga AM, Popa-Wagner A, Dumitrascu DL. The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations. J Mol Psychiatry. 2014; 2: 4.

[179]

Babulas V, Factor-Litvak P, Goetz R, Schaefer CA, Brown AS. Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. Am J Psychiatry. 2006; 163: 927-9.

[180]

Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv. 2019; 5: eaau8317.

[181]

Jin Y, Kong J. Transcutaneous Vagus Nerve Stimulation: A Promising Method for Treatment of Autism Spectrum Disorders. Front Neurosci. 2017; 10: 609.

[182]

Chan KK, To CK. Do Individuals with High-Functioning Autism Who Speak a Tone Language Show Intonation Deficits? J Autism Dev Disord. 2016; 46: 1784-92.

[183]

Engineer CT, Hays SA, Kilgard MP. Vagus nerve stimulation as a potential adjuvant to behavioral therapy for autism and other neurodevelopmental disorders. J Neurodev Disord. 2017; 9: 20.

[184]

Hull MM, Madhavan D, Zaroff CM. Autistic spectrum disorder, epilepsy, and vagus nerve stimulation. Childs Nerv Syst. 2015; 31: 1377-85.

[185]

Ricci S, Businaro R, Ippoliti F, Lo Vasco VR, Massoni F, Onofri E, et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox Res. 2013; 24: 491-501.

[186]

Gouveia FV, Warsi NM, Suresh H, Matin R, Ibrahim GM. Neurostimulation treatments for epilepsy: Deep brain stimulation, responsive neurostimulation and vagus nerve stimulation. Neurotherapeutics. 2024; 21: e00308.

[187]

Jiao D, Xu L, Gu Z, Yan H, Shen D, Gu X. Pathogenesis, diagnosis, and treatment of epilepsy: electromagnetic stimulation-mediated neuromodulation therapy and new technologies. Neural Regen Res. 2025; 20: 917-35.

[188]

Bonaz B, Sinniger V, Pellissier S. Vagus Nerve Stimulation at the Interface of Brain-Gut Interactions. Cold Spring Harb Perspect Med. 2019; 9: a034199.

[189]

Bonaz B, Sinniger V, Pellissier S. Therapeutic Potential of Vagus Nerve Stimulation for Inflammatory Bowel Diseases. Front Neurosci. 2021; 15: 650971.

[190]

Perez SM, Carreno FR, Frazer A, Lodge DJ. Vagal nerve stimulation reverses aberrant dopamine system function in the methylazoxymethanol acetate rodent model of schizophrenia. J Neurosci. 2014; 34: 9261-7.

[191]

Yap JYY, Keatch C, Lambert E, Woods W, Stoddart PR, Kameneva T. Critical Review of Transcutaneous Vagus Nerve Stimulation: Challenges for Translation to Clinical Practice. Front Neurosci. 2020; 14: 284.

[192]

Guo B, Zhang M, Hao W, Wang Y, Zhang T, Liu C. Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. Transl Psychiatry. 2023; 13: 5.

[193]

Ugwu OP, Okon MB, Alum EU, Ugwu CN, Anyanwu EG, Mariam B, et al. Unveiling the therapeutic potential of the gut microbiota-brain axis: Novel insights and clinical applications in neurological disorders. Medicine (Baltimore). 2025; 104: e43542.

[194]

Vijayaram S, Sinha R, Faggio C, Ringø E, Chou CC. Biopolymer encapsulation for improved probiotic delivery: Advancements and challenges. AIMS Microbiol. 2024; 10: 986-1023.

[195]

Talebian S, Schofield T, Valtchev P, Schindeler A, Kavanagh JM, Adil Q, et al. Biopolymer-Based Multilayer Microparticles for Probiotic Delivery to Colon. Adv Healthc Mater. 2022; 11:e2102487.

[196]

Li Z, Wang Y, Liu J, Rawding P, Bu J, Hong S, et al. Chemically and Biologically Engineered Bacteria- Based Delivery Systems for Emerging Diagnosis and Advanced Therapy. Adv Mater. 2021; 33: e2102580.

[197]

Tweedie-Cullen RY, Leong K, Wilson BC, Derraik JGB, Albert BB, Monk R, et al. Protocol for the Gut Bugs in Autism Trial: a double-blind randomised placebo-controlled trial of faecal microbiome transfer for the treatment of gastrointestinal symptoms in autistic adolescents and adults. BMJ Open. 2024; 14: e074625.

[198]

Nguyen TL, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? Dis Model Mech. 2015; 8: 1-16.

[199]

Romano K, Shah AN, Schumacher A, Zasowski C, Zhang T, Bradley-Ridout G, et al. The gut microbiome in children with mood, anxiety, and neurodevelopmental disorders: An umbrella review. Gut Microbiome (Camb). 2023; 4: e18.

[200]

Mehta N, Wang T, Friedman-Moraco RJ, Carpentieri C, Mehta AK, Rouphael N, et al. Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients. J Clin Microbiol. 2022; 60: e0016121.

[201]

Marcella C, Cui B, Kelly CR, Ianiro G, Cammarota G, Zhang F. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. Aliment Pharmacol Ther. 2021; 53: 33-42.

[202]

Rodriguez J, Cordaillat-Simmons M, Pot B, Druart C. The regulatory framework for microbiome- based therapies: insights into European regulatory developments. NPJ Biofilms Microbiomes. 2025; 11: 53.

[203]

Duhan P, Gupta B, Ahmed M, Bansal P. Gut microbiome engineering with probiotics: current trends and future directions. Discov Appl Sci. 2025; 7: 1354.

[204]

Zhang S, Li R, Xu Y, Liu R, Sun D, Dai Z. Engineered bacteria: Strategies and applications in cancer immunotherapy. Fundam Res. 2024; 5: 1327-45.

[205]

Lam KN, Spanogiannopoulos P, Soto-Perez P, Alexander M, Nalley MJ, Bisanz JE, et al. Phage- delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Rep. 2021; 37: 109930.

[206]

Rahmati R, Zarimeidani F, Ghanbari Boroujeni MR, Sadighbathi S, Kashaniasl Z, Saleh M, et al. CRISPR-Assisted Probiotic and In Situ Engineering of Gut Microbiota: A Prospect to Modification of Metabolic Disorders. Probiotics Antimicrob Proteins. 2025; 18: 1570-86.

PDF (5017KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉